Assessment of Treatment Outcome in Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors: Insight From a Resource Limited Setting
The median age of CML patients in our study was notably young. The 3-month and overall hematologic responses were excellent. The initial phase of CML at diagnosis and treatment switch was associated with the 3-month CHR, while only treatment switch was associated with the overall CHR.
Authors
- Abel Tenaw Tasamma (ORCID: https://orcid.org/0009-0000-6923-1753)
- Firehiwot Abebe Mengistie
- Solomon Tefera
- Wude Yewondwosen Awlachew
- Zekarias Tadele Alemineh
Institutions
- Debre Berhan University (ET)
- Addis Ababa University (ET)
- Aksum University (ET)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70635
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77